Appreciating HIV type 1 diversity: Subtype differences in env

AIDS Research and Human Retroviruses

Volumn 25, Issue 3, 2009, Pages 237-248

  Lynch, Rebecca M ^a   Shen, Tongye ^b,c   Gnanakaran, S ^b   Derdeyn, Cynthia A ^a,d  

^a EMORY UNIVERSITY   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

^c CENTER FOR NONLINEAR STUDIES   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MARAVIROC; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

ALPHA HELIX; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIVIRAL RESISTANCE; CELLULAR IMMUNITY; CROSS REACTION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROPHOBICITY; IN VITRO STUDY; MUTATIONAL ANALYSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VIRION; VIRUS ENTRY; VIRUS GENE; ARTICLE; CLASSIFICATION; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; IMMUNOLOGY; PHYSIOLOGY; VIROLOGY;

ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; POLYMORPHISM, GENETIC; VIRUS INTERNALIZATION;

EID: 65449188351     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0219     Document Type: Review

References (128)

1. UNAIDS-WHO: UNAIDS Annual Report. Joint United Nations Programme on HIV/AIDS and World Health Organization, Geneva, Switzerland, 2007.
2. Coffin JM: Genetic diversity and evolution of retroviruses. Curr Top Microbiol Immunol 1992;176:143-164.
3. Pathak VK andTemin HM: Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: Substitutions, frameshifts, and hypermutations. Proc Natl Acad Sci USA 1990;87(16):6019-6023.
4. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, and Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373 (6510):123-126.
5. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373(6510):117-122.
6. Ramirez BC, Simon-Loriere E, Galetto R, and Negroni M: Implications of recombination for HIV diversity. Virus Res 2008;134(1-2):64-73.
7. Peeters M, Toure-Kane C, and Nkengasong JN: Genetic diversity of HIV in Africa: Impact on diagnosis, treatment, vaccine development and trials. AIDS 2003;17(18):2547-2560.
8. McCutchan F: Global epidemiology of HIV. J Med Virol 2006;78(S1):S7-S12.
9. Korber B, Muldoon M, Theiler J, et al.: Timing the ancestor of the HIV-1 pandemic strains. Science 2000;288(5472): 1789-1796.
10. Worobey M, Gemmel M, Teuwen DE, et al.: Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature 2008;455(7213):661-664.
11. Zhu T, Korber BT, Nahmias AJ, Hooper E, Sharp PM, and Ho DD: An African HIV-1 sequence from 1959 and implications for the origin of the epidemic. Nature 1998;391 (6667):594-597.
12. Taylor BS, Sobieszczyk ME, McCutchan FE, and Hammer SM: The challenge of HIV-1 subtype diversity. N Engl J Med 2008;358(15):1590-1602.
13. Hemelaar J, Gouws E, Ghys PD, and Osmanov S: Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006;20(16):W13-23.
14. Bjorndal A, Sonnerborg A, Tscherning C, Albert J, and Fenyo EM: Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS Res Hum Retroviruses 1999;15(7): 647-653.
15. De Wolf F, Hogervorst E, Goudsmit J, et al.: Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: Phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses 1994;10(11):138 7-1400.
16. Morris L, Cilliers T, Bredell H, Phoswa M, and Martin DJ: CCR5 is the major coreceptor used by HIV-1 subtype C isolates from patients with active tuberculosis. AIDS Res Hum Retroviruses 2001;17(8):697-701.
17. Cilliers T, Nhlapo J, Coetzer M, et al.: The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol 2003;77(7):4449-4456.
18. Batra M, Tien PC, Shafer RW, Contag CH, and Katzenstein DA: HIV type 1 envelope subtype C sequences from recent seroconverters in Zimbabwe. AIDS Res Hum Ret-roviruses 2000;16:973-979.
19. Coetzer M, Cilliers T, Ping LH, Swanstrom R, and Morris L: Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. Virology 2006; 356(1-2):95-105.
20. Choge I, Cilliers T, Walker P, et al.: Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. AIDS Res Hum Retroviruses 2006;22(5):458-465.
21. Huang W, Eshleman SH, Toma J, et al.: Coreceptor tropism in human immunodeficiency virus type 1 subtype D: High prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol 2007;81(15):7885-7893.
22. Abebe A, Demissie D, Goudsmit J, et al.: HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. AIDS 1999;13(11):1305-1311.
23. Peeters M, Vincent R, Perret JL, et al.: Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: Syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20(2):115-121.
24. Treurnicht FK, Smith TL, Engelbrecht S, et al.: Genotypic and phenotypic analysis of the env gene from South African HIV-1 subtype B and C isolates. J Med Virol 2002; 68(2):141-146.
25. Tscherning C, Alaeus A, Fredriksson R, et al.: Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology 1998;241(2):181-188.
26. Utaipat U, Duerr A, Rudolph DL, et al.: Coreceptor utilization of HIV type 1 subtype E viral isolates from Thai men with HIV type 1-infected and uninfected wives. AIDS Res Hum Retroviruses 2002;18(1):1-11.
27. Zhong P, Bu S, Konings F, et al.: Genetic and biological properties of HIV type 1 isolates prevalent in villagers of the Cameroon equatorial rain forests and grass fields: Further evidence of broad HIV type 1 genetic diversity. AIDS Res Hum Retroviruses 2003;19(12):1167-1178.
28. Ping LH, Nelson JA, Hoffman IF, et al.: Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: Underrepre-sentation of X4 variants. J Virol 1999;73(8):6271-6281.
29. Cecilia D, Kulkarni SS, Tripathy SP, Gangakhedkar RR, Paranjape RS, and Gadkari DA: Absenceofcoreceptor switch with disease progression in human immunodeficiency virus infections in India. Virology 2000;271(2):253-258.
30. Williamson C, Morris L, Maughan MF, et al.: Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses 2003; 19(2):133-144.
31. Ball SC, Abraha A, Collins KR, et al.: Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J Virol 2003;77(2):1021-1038.
32. Marozsan AJ, Moore DM, Lobritz MA, et al.: Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry. J Virol 2005;79(11):7121-7134.
33. Vasan A, Renjifo B, Hertzmark E, et al.: Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 2006;42(6):843-852.
34. Baeten JM, Chohan B, Lavreys L, et al.: HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis 2007;195(8):1177-1180.
35. Rangsin R, Piyaraj P, Sirisanthana T, Sirisopana N, Short O, and Nelson KE: The natural history of HIV-1 subtype E infection in young men in Thailand with up to 14 years of follow-up. AIDS 2007;21(Suppl. 6):S39-46.
36. Kiwanuka N, Laeyendecker O, Robb M, et al.: Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis 2008;197(5):707-713.
37. Chohan B, Lang D, Sagar M, et al.: Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol 2005;79(10):6528-6531.
38. Frost SD, Liu Y, Pond SL, et al.: Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol 2005;79(10):6523-6527.
39. Derdeyn CA, Decker JM, Bibollet-Ruche F, et al.: Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004;303(5666):2019-2022.
40. Gray ES, Moore PL, Pantophlet RA, and Morris L: N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization. J Virol 2007;81(19):10769-10776.
41. Li B, Decker JM, Johnson RW, et al.: Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol 2006;80(11):5211-5218.
42. Krachmarov CP, Honnen WJ, Kayman SC, Gorny MK, Zolla-Pazner S, and Pinter A: Factors determining the breadth and potency of neutralization by v3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1. J Virol 2006;80(14):7127-7135.
43. John-Stewart GC, Nduati RW, Rousseau CM, et al.: Subtype C Is associated with increased vaginal shedding of HIV-1. J Infect Dis 2005;192(3):492-496.
44. Travers SA, O'Connell MJ, McCormack GP, and McInerney JO: Evidence for heterogeneous selective pressures in the evolution of the env gene in different human immunodeficiency virus type 1 subtypes. J Virol 2005;79(3):1836-1841.
45. Choisy M, Woelk CH, Guegan JF, and Robertson DL: Comparative study of adaptive molecular evolution in different human immunodeficiency virus groups andsubtypes. J Virol 2004;78(4):1962-1970.
46. Korber BT, MacInnes K, Smith RF, and Myers G: Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1. J Virol 1994;68(10):6730-6744.
47. Gaschen B, Taylor J, Yusim K, et al.: Diversity considerations in HIV-1 vaccine selection. Science 2002;296(5577): 2354-2360.
48. Patel MB, Hoffman NG, and Swanstrom R: Subtypespecific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins. J Virol 2007;82(2):903-916.
49. Felsovalyi K, Nadas A, Zolla-Pazner S, and Cardozo T: Distinct sequence patterns characterize the V3 region of HIV type 1gp120 from subtypes A and C. AIDS Res Hum Retroviruses 2006;22(7):703-708.
50. Hunter E: Viral entry and receptors. In: Retroviruses (Goff, S, Coffin JM, Hughes SH, and Varmus HE, eds.). Cold Spring Harbor Laboratory Press, Plainview, NY, 1997, pp. 71-121.
51. Kwong PD, Wyatt R, Majeed S, et al.: Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure Fold Des 2000;8(12):1329-1339.
52. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, and Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998;393(6686):648-659.
53. Chen B, Vogan EM, Gong H, Skehel JJ, Wiley DC, and Harrison SC: Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 2005;433(7028):834-841.
54. Huang CC, Tang M, Zhang MY, et al.: Structure of a V3-containing HIV-1 gp120 core. Science 2005;310(5750):1025-1028.
55. Zhou T, Xu L, Dey B, et al.: Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007; 445(7129):732-737.
56. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, and Detours V: Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001;58:19-42.
57. Gnanakaran S, Lang D, Daniels M, Bhattacharya T, Derdeyn CA, and Korber B: Clade specific differences in HIV-1: Diversity and correlations in C3-V4 regions of gp120. J Virol 2007;81(9):4886-4891.
58. Rong R, Gnanakaran S, Decker JM, et al.: Unique mutational patterns in the envelope {alpha}2 amphipathic helix and acquisition of length in gp120 hyper-variable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. J Virol 2007;81(11):5658-5668.
59. Borrow P, Lewicki H, Wei X, et al.: Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997;3(2):205-211.
60. Frost SD, Wrin T, Smith DM, et al.: Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci USA 2005;102(51):18514-18519.
61. Streeck H, Li B, Poon AF, et al.: Immune-driven recombination and loss of control after HIV superinfection. J Exp Med 2008;205(8):1789-1796.
62. Bunnik EM, Pisas L, van Nuenen AC, and Schuitemaker H: Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol 2008; 82(16):7932-7941.
63. Navis M, Matas DE, Rachinger A, et al.: Molecular evolution of human immunodeficiency virus type 1 upon transmission between human leukocyte antigen disparate donor-recipient pairs. PLoS ONE 2008;3(6):e2422.
64. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, and Shaw GM: Antibody neutralization and escape by HIV-1. Nature 2003; 422:307-312.
65. Rong R, Bibollet-Ruche F, Mulenga J, Allen S, Blackwell JL, and Derdeyn CA: Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J Virol 2007;81(3):1350-1359.
66. Mink M, Mosier SM, Janumpalli S, et al.: Impact of human immunodeficiency virus type 1gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol 2005;79(19):12447-12454.
67. Heil ML, Decker JM, Sfakianos JN, Shaw GM, Hunter E, and Derdeyn CA: Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site. J Virol 2004;78(14):7582-7589.
68. Holguin A, De Arellano ER, and Soriano V: Amino acid conservation in the gp41 transmembrane protein and natural polymorphisms associated with enfuvirtide resistance across HIV-1 variants. AIDS Res Hum Retroviruses 2007; 23(9):1067-1074.
69. Holguin A, Faudon JL, Labernardiere JL, and Soriano V: Susceptibility of HIV-1 non-B subtypes and recombinant variants to enfuvirtide. J Clin Virol 2007;38(2):176-180.
70. Sanders RW, Korber B, Lu M, Berkhout B, and Moore JP: Mutational analyses and natural variability of the gp41 ectodomain. In: HIV Sequence Compendium (Kuiken C, Foley B, Freed E, et al., eds.). Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 2002, pp. I23-I47.
71. Razzolini F, Vicenti I, Saladini F, et al.: Natural variability in the HR-1 and HR-2 domains of HIV type 1gp41 from different clades circulating in Italy. AIDS Res Hum Retroviruses 2007;23(4):558-563.
72. Eshleman SH, Hudelson SE, Bruce R, et al.: Analysis of HIV type 1gp41 sequences in diverse HIV type 1 strains. AIDS Res Hum Retroviruses 2007;23(12):1593-1598.
73. Cilliers T, Patience T, Pillay C, Papathanasopoulos M, and Morris L: Sensitivity of HIV type 1 subtype C isolates to the entry inhibitor T-20. AIDS Res Hum Retroviruses 2004; 20(5):477-482.
74. Chinnadurai R, Munch J, Dittmar MT, and Kirchhoff F: Inhibition of HIV-1 group M and O isolates by fusion inhibitors. AIDS 2005;19(16):1919-1922.
75. Fleury HJ, Toni T, Lan NT, et al.: Susceptibility to antiretroviral drugs of CRF01-AE, CRF02-AG, and subtype C viruses from untreated patients of Africa and Asia: Comparative genotypic and phenotypic data. AIDS Res Hum Retroviruses 2006;22(4):357-366.
76. Gray ES, Moore PL, Bibollet-Ruche F, et al.: 4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response. J Virol 2008;82(5):2367-2375.
77. Yuste E, Sanford HB, Carmody J, et al.: Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: Replication, neutralization, and survey of HIV-1-positive plasma. J Virol 2006; 80(6):3030-3041.
78. Binley JM, Lybarger EA, Crooks ET, et al.: Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 2008;82:11651-11668.
79. Binley JM, Wrin T, Korber B, et al.: Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004;78(23):13232-13252.
80. Zwick MB, Jensen R, Church S, et al.: Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 2005;79(2):1252-1261.
81. Brunel FM, Zwick MB, Cardoso RM, et al.: Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody. J Virol 2006;80(4):1680-1687.
82. Cardozo T, Kimura T, Philpott S, Weiser B, Burger H, and Zolla-Pazner S: Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res Hum Retroviruses 2007;23(3):415-426.
83. Cormier EG and Dragic T: The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J Virol 2002;76(17):8953-8957.
84. Trkola A, Dragic T, Arthos J, et al.: CD4-dependent, antibody-sensitive interactions between HIV-1 and its coreceptor CCR-5. Nature 1996;384(6605):184-187.
85. Connor RI, Sheridan KE, Ceradini D, Choe S, and Landau NR: Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185:621-628.
86. Zhang LQ, MacKenzie P, Cleland A, Holmes EC, Brown AJ, and Simmonds P: Selection for specific sequences in the external envelopeproteinofhuman immunodeficiencyvirus type 1 upon primary infection. J Virol 1993;67(6):3345-3356.
87. Zhu T, Mo H, Wang N, et al.: Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993;261(5125):1179-1181.
88. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al.: Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008;105(21):7552-7557.
89. Li M, Gao F, Mascola JR, et al.: Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005;79(16):10108-10125.
90. Li M, Salazar-Gonzalez JF, Derdeyn CA, et al.: Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 2006;80(23):11776-11790.
91. Gray ES, Moore PL, Choge IA, et al.: Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 2007;81(12):6187-6196.
92. Krachmarov C, Pinter A, Honnen WJ, et al.: Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking. J Virol 2005;79(2):780-790.
93. Kraft Z, Strouss K, Sutton WF, et al.: Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses. J Virol 2008;82(12):5912-5921.
94. Ching LK, Vlachogiannis G, Bosch KA, and Stamatatos L: The first hypervariable region of the gp120 Env glycopro-tein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen. J Virol 2008;82(2):949-956.
95. Derby NR, Kraft Z, Kan E, et al.: Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: Comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. J Virol 2006;80(17):8745-8762.
96. Stanfield RL, Gorny MK, Zolla-Pazner S, and Wilson IA: Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity. J Virol 2006;80(12):6093-6105.
97. Dorr P, Westby M, Dobbs S, et al.: Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49(11):4721-4732.
98. Kuhmann SE, Pugach P, Kunstman KJ, et al.: Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol 2004;78(6):2790-2807.
99. Anastassopoulou CG, Marozsan AJ, Matet A, et al.: Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss. PLoS Pathog 2007;3(6):e79.
100. Marozsan AJ, Kuhmann SE, Morgan T, et al.: Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 2005;338(1):182-199.
101. Tsibris AM, Sagar M, Gulick RM, et al.: In vivo emergence of vicriviroc resistanceinahuman immunodeficiency virustype 1 subtype C-infected subject. J Virol 2008;82(16):8210-8214.
102. Pugach P, Marozsan AJ, Ketas TJ, Landes EL, Moore JP, and Kuhmann SE: HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007;361(1):212-228.
103. Westby M, Smith-Burchnell C, Mori J, et al.: Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007;81(5):2359-2371.
104. Daar ES: Emerging resistance profiles of newly approved antiretroviral drugs. Top HIV Med 2008;16(4):110-116.
105. Westby M, Lewis M, Whitcomb J, et al.: Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006;80(10):4909- 4920.
106. Tersmette M, Lange JM, de Goede RE, et al.: Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet 1989;1:983-985.
107. Schuitemaker H, Koot M, Kootstra NA, et al.: Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992;66(3):1354-1360.
108. Richman DD and Bozzette SA: The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994;169:968-974.
109. Bures R, Morris L, Williamson C, et al.: Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol 2002;76(5):2233-2244.
110. Ndung'u T, Sepako E, McLane MF, et al.: HIV-1 subtype C in vitro growth and coreceptor utilization. Virology 2006; 347(2):247-260.
111. Sullivan P, Decker WD, Mulenga J, et al.: Coreceptor usage in seroconverting and transmitted partners in HIV transmissions in Lusaka, Zambia. AIDS Vaccine 2008;24:70.
112. Blish CA, Nedellec R, Mandaliya K, Mosier DE, and Over-baugh J: HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS 2007;21(6):693-702.
113. Rainwater SM, Wu X, Nduati R, et al.: Cloning and characterization of functional subtype A HIV-1 envelope variants transmitted through breastfeeding. Curr HIV Res 2007;5(2):189-197.
114. Brandful JA, Coetzer ME, Cilliers T, et al.: Phenotypic characterization of HIV type 1 isolates from Ghana. AIDS Res Hum Retroviruses 2007;23(1):144-152.
115. Perez-Alvarez L, Munoz M, Delgado E, et al.: Isolation and biological characterization of HIV-1 BG intersubtype recombinants and other genetic forms circulating in Galicia, Spain. J Med Virol 2006;78(12):1520-1528.
116. Gilbert PB, Novitsky V, and Essex M: Covariability of selected amino acid positions for HIV type 1 subtypes C and B. AIDS Res Hum Retroviruses 2005;21(12):1016-1030.
117. Richman DD, Wrin T, Little SJ, and Petropoulos CJ: Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003;100(7): 4144-4149.
118. Moore PL, Gray ES, Choge IA, et al.: The C3-V4 region is a major target of autologous neutralizing antibodies in Hiv-1 subtype C infection. J Virol 2007;82(4):1860-1869.
119. Moore PL, Crooks ET, Porter L, et al.: Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 2006;80(5):2515-2528.
120. Brown BK, Wieczorek L, Sanders-Buell E, et al.: Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 2008;375(2):529-538.
121. Rademeyer C, Moore PL, Taylor N, et al.: Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. Virology 2007;368(1):172-181.
122. Gray ES, Meyers T, Gray G, Montefiori DC, and Morris L: Insensitivityofpaediatric HIV-1 subtypeCvirusestobroadly neutralising monoclonal antibodies raised against subtype B. PLoS Med 2006;3(7):e255.
123. Zolla-Pazner S, Zhong P, Revesz K, et al.: The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1. AIDS Res Hum Retroviruses 2004;20(11):1254-1258.
124. Gorny MK, Williams C, Volsky B, et al.: Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1. J Virol 2006;80(14):6865-6872.
125. Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, and Kayman SC: The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 2004;78(10):5205-5215.
126. Burke VJ, Kim S, Williams C, Gorny MK, Zolla-Pazner S, and Kong X: Structural characterization of neutralizing human anti-V3 monoclonal antibodies 3074 and 268-D. AIDS Vaccine 2008:24.
127. Aasa-Chapman MM, Hayman A, Newton P, et al.: Development of the antibody response in acute HIV-1 infection. AIDS 2004;18(3):371-381.
128. Arendrup M, Nielsen C, Hansen JE, Pedersen C, Mathiesen L, and Nielsen JO: Autologous HIV-1 neutralizing-antibodies: Emergence of neutralization- resistant escape virus and subsequent development of escape virus neutralizing antibodies. J Acquir Immune Defic Syndr 1992;5(3): 303-307.